Terence Flynn
Stock Analyst at Morgan Stanley
(3.97)
# 647
Out of 4,735 analysts
172
Total ratings
53.76%
Success rate
9.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Equal-Weight | $123 → $113 | $96.30 | +17.35% | 15 | Jan 21, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $231 → $224 | $172.07 | +30.18% | 13 | Nov 12, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $39 | $57.25 | -31.88% | 10 | Nov 12, 2024 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $169 → $175 | $147.96 | +18.28% | 18 | Oct 16, 2024 | |
| BNTX BioNTech SE | Upgrades: Overweight | $93 → $145 | $112.02 | +29.45% | 1 | Sep 24, 2024 | |
| GPCR Structure Therapeutics | Initiates: Overweight | $118 | $27.95 | +322.18% | 1 | Sep 23, 2024 | |
| LLY Eli Lilly | Reiterates: Overweight | $1,106 | $728.63 | +51.79% | 18 | Aug 27, 2024 | |
| BHVN Biohaven | Initiates: Overweight | $58 | $38.75 | +49.70% | 1 | Jul 24, 2024 | |
| ALMS Alumis | Initiates: Overweight | $36 | $7.44 | +383.87% | 1 | Jul 23, 2024 | |
| RPRX Royalty Pharma | Maintains: Overweight | $48 → $51 | $30.66 | +66.37% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $310 → $303 | $272.19 | +11.32% | 5 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $310 → $321 | $363.52 | -11.70% | 8 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $38 → $40 | $14.09 | +183.89% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $109.85 | +52.94% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $29 | $26.42 | +9.76% | 13 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $10 | $19.71 | -49.26% | 3 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $46 → $48 | $41.24 | +16.39% | 6 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $3.93 | +103.56% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $20 | $18.26 | +9.53% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $85 | $9.76 | +770.90% | 4 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $12 | $3.65 | +229.22% | 9 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $22 | $15.78 | +39.42% | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $140.79 | +209.69% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $256.01 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.55 | - | 1 | Jul 21, 2017 |
Merck & Co.
Jan 21, 2025
Maintains: Equal-Weight
Price Target: $123 → $113
Current: $96.30
Upside: +17.35%
AbbVie
Nov 12, 2024
Maintains: Overweight
Price Target: $231 → $224
Current: $172.07
Upside: +30.18%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $57.25
Upside: -31.88%
Johnson & Johnson
Oct 16, 2024
Maintains: Equal-Weight
Price Target: $169 → $175
Current: $147.96
Upside: +18.28%
BioNTech SE
Sep 24, 2024
Upgrades: Overweight
Price Target: $93 → $145
Current: $112.02
Upside: +29.45%
Structure Therapeutics
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $27.95
Upside: +322.18%
Eli Lilly
Aug 27, 2024
Reiterates: Overweight
Price Target: $1,106
Current: $728.63
Upside: +51.79%
Biohaven
Jul 24, 2024
Initiates: Overweight
Price Target: $58
Current: $38.75
Upside: +49.70%
Alumis
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $7.44
Upside: +383.87%
Royalty Pharma
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $30.66
Upside: +66.37%
Jul 11, 2024
Maintains: Equal-Weight
Price Target: $310 → $303
Current: $272.19
Upside: +11.32%
Jul 11, 2024
Downgrades: Equal-Weight
Price Target: $310 → $321
Current: $363.52
Upside: -11.70%
May 13, 2024
Maintains: Overweight
Price Target: $38 → $40
Current: $14.09
Upside: +183.89%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $109.85
Upside: +52.94%
May 2, 2024
Maintains: Equal-Weight
Price Target: $28 → $29
Current: $26.42
Upside: +9.76%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $19.71
Upside: -49.26%
Feb 26, 2024
Maintains: Underweight
Price Target: $46 → $48
Current: $41.24
Upside: +16.39%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $3.93
Upside: +103.56%
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $32 → $20
Current: $18.26
Upside: +9.53%
Nov 13, 2023
Maintains: Overweight
Price Target: $90 → $85
Current: $9.76
Upside: +770.90%
Oct 11, 2023
Maintains: Equal-Weight
Price Target: $25 → $12
Current: $3.65
Upside: +229.22%
Oct 11, 2023
Maintains: Equal-Weight
Price Target: $27 → $22
Current: $15.78
Upside: +39.42%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $140.79
Upside: +209.69%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $256.01
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.55
Upside: -